{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-108980","form_type":"8-K","ticker":"TBPH","cik":"0001583107","company_name":"Theravance Biopharma, Inc.","filed_at":"2026-09-18T21:16:51+00:00","discovered_at":"2026-09-18T21:18:05.595057+00:00","generated_at":"2026-09-18T21:18:14.372403+00:00","sec_items":["5.07"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Shareholders approve Zymeworks merger; closing expected Sept 23, 2026","bullets":["Merger Proposal approved: 40,993,370 for, 8,671 against, 84,733 abstentions (>2/3 required).","Advisory merger-related compensation proposal also approved (40,587,829 for, 470,381 against).","Merger expected to close on or about Sept 23, 2026; Theravance to become wholly owned subsidiary of Zymeworks.","CVR Agreement contingent consideration remains subject to future payment conditions.","Quorum of 79.14% (41,086,774 shares) present; adjournment proposal not needed."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-108980","json":"https://secwatch.observer/filing/0001104659-26-108980.json","markdown":"https://secwatch.observer/filing/0001104659-26-108980.md","text":"https://secwatch.observer/filing/0001104659-26-108980.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1583107/000110465926108980/0001104659-26-108980-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1583107/000110465926108980/tm2625672d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-18T21:18:14.372403+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}